Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) EBITDA: 2022-2024

Historic EBITDA for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $65.4 million.

  • Entrada Therapeutics' EBITDA fell 244.93% to -$43.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.8 million, marking a year-over-year decrease of 283.99%. This contributed to the annual value of $65.4 million for FY2024, which is 1575.03% up from last year.
  • As of FY2024, Entrada Therapeutics' EBITDA stood at $65.4 million, which was up 1,575.03% from -$4.4 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' EBITDA ranged from a high of $65.4 million in FY2024 and a low of -$96.7 million during FY2022.
  • Its 3-year average for EBITDA is -$11.9 million, with a median of -$4.4 million in 2023.
  • Data for Entrada Therapeutics' EBITDA shows a peak YoY skyrocketed of 1,575.03% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Entrada Therapeutics' EBITDA stood at -$96.7 million in 2022, then skyrocketed by 95.41% to -$4.4 million in 2023, then soared by 1,575.03% to $65.4 million in 2024.